In 2018, osimertinib was also approved as a first-line treatment of advanced EGFR-mutant NSCLC on the basis of the results from the FLAURA trial, reporting a progression-free survival (PFS) of 18.9 months and overall survival (OS) of 38.6 months in untreated patients harboring EGFR sensitizing mutations [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.